206 related articles for article (PubMed ID: 29891120)
1. Evolving Understanding of Chronic Myelomonocytic Leukemia: Implications for Future Treatment Paradigms.
Geevarghese A; Mascarenhas J
Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):519-527. PubMed ID: 29891120
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study.
Pleyer L; Leisch M; Kourakli A; Padron E; Maciejewski JP; Xicoy Cirici B; Kaivers J; Ungerstedt J; Heibl S; Patiou P; Hunter AM; Mora E; Geissler K; Dimou M; Jimenez Lorenzo MJ; Melchardt T; Egle A; Viniou AN; Patel BJ; Arnan M; Valent P; Roubakis C; Bernal Del Castillo T; Galanopoulos A; Calabuig Muñoz M; Bonadies N; Medina de Almeida A; Cermak J; Jerez A; Montoro MJ; Cortés A; Avendaño Pita A; Lopez Andrade B; Hellstroem-Lindberg E; Germing U; Sekeres MA; List AF; Symeonidis A; Sanz GF; Larcher-Senn J; Greil R
Lancet Haematol; 2021 Feb; 8(2):e135-e148. PubMed ID: 33513373
[TBL] [Abstract][Full Text] [Related]
3. How I treat chronic myelomonocytic leukemia.
Solary E; Itzykson R
Blood; 2017 Jul; 130(2):126-136. PubMed ID: 28572287
[TBL] [Abstract][Full Text] [Related]
4. Chronic myelomonocytic leukemia: 2013 update on diagnosis, risk stratification, and management.
Parikh SA; Tefferi A
Am J Hematol; 2013 Nov; 88(11):967-74. PubMed ID: 23963888
[TBL] [Abstract][Full Text] [Related]
5. Generalized palisaded neutrophilic and granulomatous dermatitis-a cutaneous manifestation of chronic myelomonocytic leukemia? A clinical, histopathological, and molecular study of 3 cases.
Federmann B; Bonzheim I; Yazdi AS; Schmidt J; Fend F; Metzler G
Hum Pathol; 2017 Jun; 64():198-206. PubMed ID: 28442268
[TBL] [Abstract][Full Text] [Related]
6. Chronic Myelomonocytic Leukemia: Insights into Biology, Prognostic Factors, and Treatment.
Coltro G; Patnaik MM
Curr Oncol Rep; 2019 Nov; 21(11):101. PubMed ID: 31728739
[TBL] [Abstract][Full Text] [Related]
7. Cutting the cord from myelodysplastic syndromes: chronic myelomonocytic leukemia-specific biology and management strategies.
Padron E; Steensma DP
Curr Opin Hematol; 2015 Mar; 22(2):163-70. PubMed ID: 25575034
[TBL] [Abstract][Full Text] [Related]
8. Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents.
Alfonso A; Montalban-Bravo G; Takahashi K; Jabbour EJ; Kadia T; Ravandi F; Cortes J; Estrov Z; Borthakur G; Pemmaraju N; Konopleva M; Bueso-Ramos C; Pierce S; Kantarjian H; Garcia-Manero G
Am J Hematol; 2017 Jul; 92(7):599-606. PubMed ID: 28370097
[TBL] [Abstract][Full Text] [Related]
9. Disease-modifying activity of ruxolitinib in a patient with JAK2-negative CMML-2.
Francke S; Mies A; Meggendorfer M; Oelschlaegel U; Balaian E; Gloaguen S; Haferlach T; Ehninger G; Bornhäuser M; Platzbecker U
Leuk Lymphoma; 2017 May; 58(5):1271-1272. PubMed ID: 27659716
[No Abstract] [Full Text] [Related]
10. Cytopenia, dysplasia, and monocytosis: a precursor to chronic myelomonocytic leukemia or a distinct subgroup? Case reports and review of literature.
Singh ZN; Post GR; Kiwan E; Maddox AM
Clin Lymphoma Myeloma Leuk; 2011 Jun; 11(3):293-7. PubMed ID: 21658659
[TBL] [Abstract][Full Text] [Related]
11. Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia.
Beran M; Estey E; O'Brien SM; Giles FJ; Koller CA; Kornblau S; Keating M; Kantarjian HM
Leuk Lymphoma; 1998 Nov; 31(5-6):521-31. PubMed ID: 9922042
[TBL] [Abstract][Full Text] [Related]
12. Chronic Myelomonocytic Leukemia: a Genetic and Clinical Update.
McCullough KB; Patnaik MM
Curr Hematol Malig Rep; 2015 Sep; 10(3):292-302. PubMed ID: 26122388
[TBL] [Abstract][Full Text] [Related]
13. Current management of patients with chronic myelomonocytic leukemia.
Mora E; Sanz GF
Curr Opin Oncol; 2018 Nov; 30(6):409-417. PubMed ID: 30169461
[TBL] [Abstract][Full Text] [Related]
14. Real-world data of chronic myelomonocytic leukemia: A chinese single-center retrospective study.
Ma L; Jiang L; Yang W; Luo Y; Mei C; Zhou X; Xu G; Xu W; Ye L; Ren Y; Lu C; Lin P; Jin J; Tong H
Cancer Med; 2021 Mar; 10(5):1715-1725. PubMed ID: 33559357
[TBL] [Abstract][Full Text] [Related]
15. Contemporary Risk Stratification and Treatment of Chronic Myelomonocytic Leukemia.
Tremblay D; Rippel N; Feld J; El Jamal SM; Mascarenhas J
Oncologist; 2021 May; 26(5):406-421. PubMed ID: 33792103
[TBL] [Abstract][Full Text] [Related]
16. [Chronic myelomonocytic leukemia (CMML): recent advances in molecular pathogenesis and treatment].
Harada Y; Harada H
Rinsho Ketsueki; 2016 Feb; 57(2):147-55. PubMed ID: 26935632
[TBL] [Abstract][Full Text] [Related]
17. Chronic Myelomonocytic Leukemia With Fibrosis Is a Distinct Disease Subset With Myeloproliferative Features and Frequent JAK2 p.V617F Mutations.
Gur HD; Loghavi S; Garcia-Manero G; Routbort M; Kanagal-Shamanna R; Quesada A; Khogeer H; Pierce S; Medeiros LJ; Kantarjian H; Khoury JD
Am J Surg Pathol; 2018 Jun; 42(6):799-806. PubMed ID: 29596070
[TBL] [Abstract][Full Text] [Related]
18. Current management of patients with chronic myelomonocytic leukemia.
Alfonso A; Montalban-Bravo G; Garcia-Manero G
Curr Opin Oncol; 2017 Jan; 29(1):79-87. PubMed ID: 27849645
[TBL] [Abstract][Full Text] [Related]
19. PDE4 Differential Expression Is a Potential Prognostic Factor and Therapeutic Target in Patients With Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia.
Chamseddine AN; Cabrero M; Wei Y; Ganan-Gomez I; Colla S; Takahashi K; Yang H; Bohannan ZS; Garcia-Manero G
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S67-73. PubMed ID: 27521329
[TBL] [Abstract][Full Text] [Related]
20. Treatment advances for pediatric and adult onset neoplasms with monocytosis.
McCullough KB; Kuhn AK; Patnaik MM
Curr Hematol Malig Rep; 2021 Jun; 16(3):256-266. PubMed ID: 33728588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]